Nazia Khan1, Johanna P Daily. 1. Department of Medicine (Infectious Diseases), Albert Einstein College of Medicine, Bronx, New York, USA.
Abstract
PURPOSE OF REVIEW: This is a review of Plasmodium vivax epidemiology, pathogenesis, disease presentation, treatment and innovations in control and elimination. Here, we examine the recent literature and summarize new advances and ongoing challenges in the management of P. vivax . RECENT FINDINGS: P. vivax has a complex life cycle in the human host which impacts disease severity and treatment regimens. There is increasing data for the presence of cryptic reservoirs in the spleen and bone marrow which may contribute to chronic vivax infections and possibly disease severity. Methods to map the geospatial epidemiology of P. vivax chloroquine resistance are advancing, and they will inform local treatment guidelines. P. vivax treatment requires an 8-aminoquinoline to eradicate the dormant liver stage. Evidence suggests that higher doses of 8-aminoquinolines may be needed for radical cure of tropical frequent-relapsing strains. SUMMARY: P. vivax is a significant global health problem. There have been recent developments in understanding the complexity of P. vivax biology and optimization of antimalarial therapy. Studies toward the development of best practices for P. vivax control and elimination programs are ongoing.
PURPOSE OF REVIEW: This is a review of Plasmodium vivax epidemiology, pathogenesis, disease presentation, treatment and innovations in control and elimination. Here, we examine the recent literature and summarize new advances and ongoing challenges in the management of P. vivax . RECENT FINDINGS: P. vivax has a complex life cycle in the human host which impacts disease severity and treatment regimens. There is increasing data for the presence of cryptic reservoirs in the spleen and bone marrow which may contribute to chronic vivax infections and possibly disease severity. Methods to map the geospatial epidemiology of P. vivax chloroquine resistance are advancing, and they will inform local treatment guidelines. P. vivax treatment requires an 8-aminoquinoline to eradicate the dormant liver stage. Evidence suggests that higher doses of 8-aminoquinolines may be needed for radical cure of tropical frequent-relapsing strains. SUMMARY: P. vivax is a significant global health problem. There have been recent developments in understanding the complexity of P. vivax biology and optimization of antimalarial therapy. Studies toward the development of best practices for P. vivax control and elimination programs are ongoing.
Authors: Nathália N Chamma-Siqueira; Suiane C Negreiros; Sarah-Blythe Ballard; Sâmela Farias; Sandro P Silva; Stella M Chenet; Eduardo J M Santos; Luann W Pereira de Sena; Flávia Póvoa da Costa; Amanda G N Cardoso-Mello; Paola B Marchesini; Cássio R L Peterka; Giselle M R Viana; Alexandre Macedo de Oliveira Journal: N Engl J Med Date: 2022-03-31 Impact factor: 176.079
Authors: Steven Kho; Labibah Qotrunnada; Leo Leonardo; Benediktus Andries; Putu A I Wardani; Aurelie Fricot; Benoit Henry; David Hardy; Nur I Margyaningsih; Dwi Apriyanti; Agatha M Puspitasari; Pak Prayoga; Leily Trianty; Enny Kenangalem; Fabrice Chretien; Valentine Brousse; Innocent Safeukui; Hernando A Del Portillo; Carmen Fernandez-Becerra; Elamaran Meibalan; Matthias Marti; Ric N Price; Tonia Woodberry; Papa A Ndour; Bruce M Russell; Tsin W Yeo; Gabriela Minigo; Rintis Noviyanti; Jeanne R Poespoprodjo; Nurjati C Siregar; Pierre A Buffet; Nicholas M Anstey Journal: PLoS Med Date: 2021-05-26 Impact factor: 11.069
Authors: Catalina Tovar-Acero; María Camila Velasco; Paula Andrea Avilés-Vergara; Dina Marcela Ricardo-Caldera; Erasmo Manuel Alvis; Javier Ramirez-Montoya; Maria Fernanda Yasnot Acosta Journal: Parasite Epidemiol Control Date: 2021-01-25